-DOCSTART- -X- O
While -X- _ O
impressive -X- _ O
clinical -X- _ O
responses -X- _ O
have -X- _ O
been -X- _ O
observed -X- _ O
using -X- _ O
chimeric -X- _ B-Intervention
antigen -X- _ I-Intervention
receptor -X- _ I-Intervention
( -X- _ I-Intervention
CAR -X- _ I-Intervention
) -X- _ I-Intervention
T -X- _ I-Intervention
cells -X- _ I-Intervention
targeting -X- _ I-Intervention
CD19+ -X- _ I-Intervention
hematologic -X- _ I-Intervention
malignancies -X- _ I-Intervention
, -X- _ O
limited -X- _ O
clinical -X- _ O
benefit -X- _ O
has -X- _ O
been -X- _ O
observed -X- _ O
using -X- _ O
CAR -X- _ O
T -X- _ O
cells -X- _ O
for -X- _ O
a -X- _ O
variety -X- _ O
of -X- _ O
solid -X- _ B-Patient
tumors. -X- _ I-Patient
Results -X- _ O
of -X- _ O
clinical -X- _ O
studies -X- _ O
have -X- _ O
highlighted -X- _ O
several -X- _ B-Outcome
obstacles -X- _ I-Outcome
which -X- _ I-Outcome
CAR -X- _ I-Outcome
T -X- _ I-Outcome
cells -X- _ I-Outcome
face -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
context -X- _ I-Outcome
of -X- _ I-Outcome
solid -X- _ I-Outcome
tumors -X- _ I-Outcome
, -X- _ I-Outcome
including -X- _ I-Outcome
insufficient -X- _ I-Outcome
homing -X- _ I-Outcome
to -X- _ I-Outcome
tumor -X- _ I-Outcome
sites -X- _ I-Outcome
, -X- _ I-Outcome
lack -X- _ I-Outcome
of -X- _ I-Outcome
expansion -X- _ I-Outcome
and -X- _ I-Outcome
persistence -X- _ I-Outcome
, -X- _ I-Outcome
encountering -X- _ I-Outcome
a -X- _ I-Outcome
highly -X- _ I-Outcome
immunosuppressive -X- _ I-Outcome
tumor -X- _ I-Outcome
microenvironment -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
heterogeneous -X- _ I-Outcome
antigen -X- _ I-Outcome
expression. -X- _ I-Outcome
In -X- _ O
this -X- _ O
review -X- _ O
, -X- _ O
we -X- _ O
review -X- _ O
clinical -X- _ O
outcomes -X- _ O
and -X- _ O
discuss -X- _ O
strategies -X- _ O
to -X- _ O
improve -X- _ O
the -X- _ O
antitumor -X- _ O
activity -X- _ O
of -X- _ O
CAR -X- _ O
T -X- _ O
cells -X- _ O
for -X- _ O
solid -X- _ B-Patient
tumors -X- _ I-Patient
. -X- _ O

